Spinal Cord Stimulation

1.What Problem Is SCS Actually Solving?

The most important preoperative question is not “Has the patient failed conservative therapy?” It is more specific: is the dominant pain generator neuropathic, anatomically plausible, refractory, and measurable? SCS is best supported when the patient’s pain is burning, electric, allodynic, shooting, distal, radicular, or otherwise neuropathic. It is less reliable when the dominant complaint is axial mechanical pain from instability, severe stenosis, deformity, fracture, inflammatory arthropathy, or another nociceptive driver that has not been addressed.

Modern SCS works through several stimulation paradigms. Traditional tonic SCS creates paresthesia over the painful territory. High-frequency 10 kHz stimulation is paresthesia-free. Burst and differential targeted multiplexed programs attempt to modulate pain networks without relying entirely on paresthesia overlap. Closed-loop systems record evoked compound action potentials and adjust output to maintain a target dose of neural activation. These distinctions matter, but they do not rescue poor selection. The phenotype still comes first.

2.The Published Consensus Spine

The public guidance most useful for trainees comes from two overlapping families of work. First, the Neurostimulation Appropriateness Consensus Committee, or NACC, has published practical recommendations on infection prevention, surgical technique, neurologic-injury mitigation, cervical neurostimulation, and long-term optimization or salvage. Second, multisociety consensus guidance on patient selection and trial stimulation emphasizes psychological screening, anticoagulation and infection risk, trial interpretation, and expectation-setting.

Those documents do not replace local protocols, device labeling, or judgment. They do, however, give trainees a reliable safety culture: optimize modifiable infection risk, respect neuraxial anticoagulation rules, avoid deep sedation when patient feedback is needed, document device MRI conditionality, and make the trial answer a predefined clinical question rather than a vibe check.

3.Vocabulary That Changes Management

4.Painful Diabetic Neuropathy: The Strong New Indication

Painful diabetic neuropathy is the modern SCS indication that most clearly changed the teaching script. The SENZA-PDN randomized trial compared conventional medical management alone with conventional medical management plus high-frequency 10 kHz SCS in patients with refractory lower-limb painful diabetic neuropathy. The SCS group had large and durable improvements in pain and quality of life, with follow-up reported through 24 months and longer-term survey data extending the durability story.

That does not mean every patient with diabetes and foot pain should be sent for an implant. It means that after neuropathic medications, diabetes care, foot care, and vascular/infection risks are addressed, SCS should be part of the discussion for persistent disabling PDN. The patient needs a foot exam, a realistic discussion of wound and infection risk, and a clear understanding that the primary goal is pain and function, not “curing neuropathy.”

5.Nonsurgical Refractory Back Pain: Not a Shortcut Around Surgery

PSPS Type 1 and nonsurgical refractory back pain describe patients with chronic refractory back pain, with or without leg pain, who have not had prior spine surgery and are not appropriate candidates for corrective spine surgery. This category matters because randomized and prospective data support SCS in selected patients, including high-frequency and burst paradigms. It also matters because it can be abused if we use it before doing the harder diagnostic work.

The trainee’s job is to make sure “nonsurgical” really means nonsurgical. The patient should have appropriate imaging, surgical assessment when indicated, rehabilitation, behavioral health review, and nonoperative/interventional care. Progressive neurologic deficit, untreated severe stenosis, instability, deformity, fracture, infection, malignancy, or inflammatory disease should not be bypassed by an SCS referral.

6.Length-Dependent Peripheral Neuropathy: Same Shape, Weaker Evidence

Length-dependent peripheral neuropathy is clinically seductive because it can look like PDN: distal burning, painful numbness, allodynia, and stocking-glove symptoms. But evidence does not transfer automatically. A patient with chemotherapy-induced neuropathy, idiopathic small-fiber neuropathy, B12 deficiency, paraproteinemia, alcohol-related neuropathy, hereditary neuropathy, or autoimmune neuropathy is not the same evidence object as a SENZA-PDN patient.

That does not make SCS unreasonable. It makes the conversation more individualized. Before a trial, confirm the diagnosis and look for treatable causes: diabetes or prediabetes, B12 deficiency, thyroid disease, renal disease, paraproteinemia, alcohol or toxin exposure, medication toxicity, autoimmune disease, and hereditary patterns. If the neuropathy remains severe, refractory, and function-limiting, a trial can be considered, but the patient should know that the evidence base is less mature.

7.SCI and MS Central Pain: Proceed With Humility

Central neuropathic pain is different. In spinal cord injury, the pain may be at-level, below-level, radicular, musculoskeletal, spasticity-related, pressure-injury-related, or mixed. In multiple sclerosis, pain can come from central lesions, spasticity, trigeminal neuralgia, musculoskeletal compensation, or treatment effects. SCS may help selected patients, but the outcomes are less predictable than in peripheral neuropathic pain.

The most defensible posture is careful selection and honest uncertainty. Optimize spasticity, sleep, mood, rehabilitation, pressure injury, bowel/bladder triggers, and medication burden first. Ask neurology and rehabilitation colleagues to help define the pain phenotype. If a trial is offered, define a specific target symptom, such as lower-extremity burning pain, not global weakness, fatigue, gait decline, or “quality of life” in the abstract.

8.Before the Trial, Define Success

The old shorthand is “at least 50% pain relief.” That remains useful, but it is too narrow. For paresthesia-based therapy, the trial asks whether stimulation covers the painful territory and whether the induced sensation is tolerable. For paresthesia-free therapy, the patient may never feel stimulation, so you need other anchors: pain diary, walking tolerance, sleep, allodynia, medication use, patient global impression, and whether the patient understands what living with the device will require.

9.Safety Details Trainees Should Not Miss

Infection prevention starts before the prep stick. Optimize diabetes, smoking, nutrition, skin disease, immune suppression, and active infection risk. Anticoagulant and antiplatelet management should be treated with the seriousness of a neuraxial procedure. Device documentation matters: future MRI conditionality, model, lead location, restrictions, and implant date should be easy to find.

For percutaneous trial placement, avoid deep sedation or general anesthesia when patient feedback is needed, unless there is a specific technical or patient factor that justifies it. After implant, trainees should know the common failure modes: lead migration, inadequate coverage, uncomfortable stimulation, infection, wound breakdown, loss of efficacy, battery or pocket pain, need for reprogramming, revision, or explant.

10.The Modern Mental Model